Federated Hermes Inc. Has $211,000 Holdings in RxSight, Inc. (NASDAQ:RXST)

Federated Hermes Inc. decreased its stake in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 91.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 6,146 shares of the company's stock after selling 63,118 shares during the period. Federated Hermes Inc.'s holdings in RxSight were worth $211,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Private Trust Co. NA acquired a new stake in RxSight in the 4th quarter worth about $34,000. Arcadia Investment Management Corp MI acquired a new stake in shares of RxSight in the fourth quarter valued at approximately $46,000. Harbor Investment Advisory LLC acquired a new stake in RxSight during the fourth quarter worth approximately $52,000. Global Retirement Partners LLC bought a new position in RxSight during the 4th quarter worth $69,000. Finally, KBC Group NV lifted its position in shares of RxSight by 71.0% during the 4th quarter. KBC Group NV now owns 2,107 shares of the company's stock valued at $72,000 after acquiring an additional 875 shares during the period. Institutional investors and hedge funds own 78.78% of the company's stock.

Insider Transactions at RxSight

In related news, Director Tamara Fountain sold 7,000 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total value of $179,970.00. Following the completion of the sale, the director now directly owns 24,793 shares in the company, valued at $637,428.03. This represents a 22.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 9.36% of the stock is owned by company insiders.

RxSight Price Performance

RXST stock traded up $0.23 during midday trading on Thursday, reaching $14.70. 166,251 shares of the stock were exchanged, compared to its average volume of 620,254. The stock has a market capitalization of $595.22 million, a PE ratio of -17.71 and a beta of 1.26. RxSight, Inc. has a 52 week low of $13.50 and a 52 week high of $66.54. The company has a fifty day moving average price of $22.76 and a 200 day moving average price of $34.43.

RxSight (NASDAQ:RXST - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.25). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The firm had revenue of $40.21 million during the quarter, compared to analyst estimates of $40.23 million. As a group, analysts anticipate that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. JPMorgan Chase & Co. reaffirmed an "underweight" rating and issued a $17.00 price target (down previously from $40.00) on shares of RxSight in a research note on Friday, April 4th. Bank of America reaffirmed an "underperform" rating and set a $22.00 price target (down previously from $36.00) on shares of RxSight in a report on Thursday, April 3rd. Wells Fargo & Company decreased their price objective on shares of RxSight from $35.00 to $22.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 3rd. Stifel Nicolaus cut their target price on RxSight from $33.00 to $28.00 and set a "hold" rating for the company in a research note on Wednesday, March 19th. Finally, UBS Group lowered RxSight from a "buy" rating to a "neutral" rating and decreased their price target for the company from $45.00 to $16.00 in a research note on Wednesday, April 9th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $37.60.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.